JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB312665

Alexa Fluor® 568 Anti-Cytochrome P450 1A2 抗体 [EPR6138(2)]

Alexa Fluor® 568 Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal Cytochrome P450 1A2 antibody - conjugated to Alexa Fluor® 568.

別名を表示する

Cytochrome P450 1A2, CYPIA2, Cholesterol 25-hydroxylase, Cytochrome P(3)450, Cytochrome P450 4, Cytochrome P450-P3, Hydroperoxy icosatetraenoate dehydratase, CYP1A2

関連する標識済み抗体及び組成の異なる製品 (6)

  • 578 PE

    PE Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]

  • 660 APC

    APC Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR6138(2)

アイソタイプ

IgG

標識

Alexa Fluor® 568

励起波長/蛍光波長

Ex: 578nm, Em: 603nm

キャリアフリー

No

アプリケーション

Target Binding Affinity, Antibody Labelling

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

製品の詳細

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle|Store in the dark

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Cytochrome P450 1A2 often known as CYP1A2 is an important enzyme in the cytochrome P450 superfamily with a known mass around 58 kDa. It is mainly expressed in the liver where it functions in the metabolism of drugs and the bioactivation of various compounds. CYP1A2 also participates in the oxidation of small organic molecules which include xenobiotics and endogenous substrates. Due to its function researchers frequently study CYP1A2 substrates and its inhibitors to understand better its role in drug metabolism and toxicity.
Biological function summary

CYP1A2 plays a central role in the oxidative biotransformation of drugs and procarcinogens. It does not form part of a larger complex but interacts dynamically with other enzymes in the detoxification process. CYP1A2 metabolizes several clinical drugs such as caffeine and theophylline and regulates the detoxification of aromatic amines and hydrocarbons. Studying CYP1A2 inhibitors can provide insights into clinically relevant drug interactions and potential side effects in pharmacotherapy.

Pathways

CYP1A2 functions within the drug metabolism and synthesis of cholesterol steroids and other lipids pathways. In the drug metabolism pathway CYP1A2 works alongside other cytochrome P450 enzymes such as CYP1A1 and CYP1B1 which together ensure the metabolism and clearance of various exogenous and endogenous compounds. These pathways are vital for maintaining drug efficacy and preventing toxicity through the metabolic clearance of pharmaceutical agents and harmful substances.

CYP1A2 activity links to liver disorders and certain cancers. Altered enzyme activity may lead to hepatotoxicity a condition that arises from excessive accumulation of active drug metabolites in the liver. Furthermore due to its role in activating procarcinogens increased CYP1A2 activity relates to a higher risk of developing certain cancers including liver cancer. Researchers often explore these connections to better understand the enzyme's role in disease pathogenesis and to develop CYP1A2-directed therapies.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed : 10681376, PubMed : 11555828, PubMed : 12865317, PubMed : 19965576, PubMed : 9435160). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed : 10681376, PubMed : 11555828, PubMed : 12865317, PubMed : 19965576, PubMed : 9435160). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed : 11555828, PubMed : 12865317). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2 (PubMed : 11555828, PubMed : 12865317). Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed : 21576599). May act as a major enzyme for all-trans retinoic acid biosynthesis in the liver. Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid (PubMed : 10681376). Primarily catalyzes stereoselective epoxidation of the last double bond of polyunsaturated fatty acids (PUFA), displaying a strong preference for the (R,S) stereoisomer (PubMed : 19965576). Catalyzes bisallylic hydroxylation and omega-1 hydroxylation of PUFA (PubMed : 9435160). May also participate in eicosanoids metabolism by converting hydroperoxide species into oxo metabolites (lipoxygenase-like reaction, NADPH-independent) (PubMed : 21068195). Plays a role in the oxidative metabolism of xenobiotics. Catalyzes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin (PubMed : 14725854). Metabolizes caffeine via N3-demethylation (Probable).
See full target information CYP1A2

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com